Dss Inc Stock Price, News & Analysis

DSS, Inc. (NYSE American: DSS) announced the launch of Liquid Value Asset Management Limited (LVAM), a Hong Kong-based investment management firm, primarily owned by its subsidiary DSS Financial Management, Inc. (DFMI). DFMI has provided a $1 million working capital loan to expedite LVAM's operations, which will commence with $9 million in proprietary trading. LVAM aims for attractive risk-adjusted returns using advanced algorithmic trading strategies. CEO Wilson Lee and his team will manage the firm, which targets scalable trading programs and rapid portfolio liquidation capabilities.

DSS, Inc. (NYSE American: DSS) announced its stock trading under a new CUSIP number effective October 1, 2021, following its name change. The company has undergone significant transformation in the past two years, focusing on high-growth markets including digital assets, healthcare, and renewable energy. COO Jason Grady emphasized this milestone as part of DSS's long-term strategy to enhance shareholder value. DSS operates a diversified business model and plans to unlock shareholder value via IPO spin-offs from its subsidiaries.

Document Security Systems (DSS) has signed a $40 million subscription agreement with American Pacific Bancorp (APB) to acquire 6,666,700 shares at $6.00 each, making DSS a majority owner of APB. This investment aims to bolster APB's capacity for diversified lending, including mortgages and medical real estate financing. DSS anticipates quick deployment of this capital to generate interest before the end of 2021, highlighting a strong validation of APB's business model.

Document Security Systems (DSS) announced a significant investment of $15 million from Alset EHome International, which will see the issuance of 12,155,591 shares at $1.234 per share. This strategic partnership indicates strong confidence from Alset in DSS and aims to enhance growth opportunities for both entities. DSS operates across multiple sectors, including blockchain security and healthcare, and has a unique business model that allows shareholders to benefit from its subsidiary IPOs. CEO Frank D. Heuszel emphasized the mutual growth potential between the companies.

Impact BioMedical, a subsidiary of DSS, and GRDG Sciences have successfully synthesized their first Quantum-based compound aimed at enhancing immune response. This achievement follows over a year of research initiated in Summer 2020. The compound, designed to improve therapeutic efficacy and combat a projected patent cliff in the pharmaceutical industry, will undergo testing at a prominent university. The development of this compound, inspired by quantum mechanics, could potentially lead to significant medical breakthroughs and a new class of medicines.

Impact Biomedical, a subsidiary of Document Security Systems (DSS), announced promising results from clinical tests of its 3FDB (DEET Booster) technology aimed at enhancing mosquito repellents. Conducted in collaboration with Global Research and Discovery Group (GRDG), the tests demonstrated significant improvement in mosquito repellency rates, outperforming DEET alone. The tests revealed a 98% repellency rate after 3 hours with a 10% 3FDB and 5% DEET mix. The results indicate potential applications in personal care products and underscore the technology's capability to address mosquito-borne diseases.

Document Security Systems, Inc. (DSS) promoted Todd D. Macko to Chief Financial Officer effective August 16, 2021. With over 25 years of public and corporate accounting experience, Macko previously served as Vice President of Finance at DSS. His expertise includes financial planning, budgeting, and mergers and acquisitions. CEO Frank D. Heuszel expressed confidence in Macko's ability to support the company's long-term strategy. DSS operates in multiple sectors including blockchain security and renewable energy, focusing on shareholder value through potential spin-offs of subsidiaries.

DSS, a multinational company, announced a $1 million equity investment in Vivacitas Oncology, a clinical-stage firm focused on difficult-to-treat cancers. This investment, made through DSS Biomedical, highlights DSS's commitment to enhancing human healthcare. Vivacitas's lead candidate, AR-67, shows promise in treating cancers resistant to current therapies, with clinical data indicating potential improvements in progression-free survival for glioblastoma patients while reducing severe side effects. The CEO of DSS expressed optimism about the strategic investment.